Vrbková Jana Ph.D.
Journals
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Tumor Biology.
2015,
36(6),
4243-52,
ISSN: 1010-4283,
PMID: 25616695,
Acute promyelocytic leukemia successfully treated also in elderly patients with significant comorbidities: a 20-year single-center experience.
Neoplasma.
2015,
62(1),
146-151,
ISSN: 0028-2685,
PMID: 25563379,
Triple negative breast cancer-BCL2 in prognosis and prediction. Review.
Current Drug Targets.
2014,
15(12),
1166-1175,
ISSN: 1389-4501,
PMID: 25374001,